Core Viewpoint - North China Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Adenosylcobalamin Capsules (0.5mg) from the National Medical Products Administration, indicating the product's compliance with quality and efficacy standards for generic drugs [1][2]. Group 1: Drug Registration Details - The Drug Registration Certificate for Adenosylcobalamin Capsules (0.5mg) was approved on July 29, 2025, after being submitted for review in April 2024 [2][4]. - Adenosylcobalamin is primarily used for the prevention and treatment of Vitamin B12 deficiency and related conditions, such as megaloblastic anemia [2][5]. Group 2: Research and Development - The company has invested a total of 10.9382 million yuan in research and development for this product [3]. - The product is expected to be produced and marketed following the receipt of the registration certificate [4]. Group 3: Market Situation - A total of 27 companies, including North China Pharmaceutical, hold the Drug Registration Certificate for Adenosylcobalamin Capsules (0.5mg) in China [5]. - The sales volume for the capsule form is projected to be approximately 29,000 units in 2024, with total sales across all forms expected to reach around 1.5 billion units, reflecting a 19% increase from 2023 [5]. Group 4: Impact on the Company - The approval of the Drug Registration Certificate enhances the company's product pipeline in hematology and hematopoietic system medications, meeting the basic requirements for centralized procurement bidding [6].

Group 1 - The core point of the article is that North China Pharmaceutical has received the drug registration certificate for Adenosylcobalamin capsules (0.5mg) from the National Medical Products Administration [2] Group 2 - The approval of the drug registration certificate indicates a significant regulatory milestone for the company [2] - This development may enhance the company's product portfolio and market competitiveness in the pharmaceutical industry [2] - The introduction of Adenosylcobalamin capsules could potentially meet the growing demand for vitamin B12 supplements in the market [2]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Adenosylcobalamin capsules (0.5mg), which are expected to have significant therapeutic benefits in treating neurological conditions [1] Company Summary - The approved product, Adenosylcobalamin capsules, is designed to inhibit abnormal fat synthesis in nerve myelin, block the occurrence and development of nerve fiber demyelination, and promote the synthesis of proteins and lipids to repair damaged nerves [1] - The capsules also lower abnormal TNFα levels, inhibit the occurrence of SACD, participate in the tricarboxylic acid cycle, and promote the metabolism of three major substances to maintain normal cellular functions [1] - The product normalizes glutathione levels to protect nerve cells and participates in heme synthesis to improve anemia [1] - The company has invested a total of 10.9382 million yuan in research and development for this product to date (unaudited) [1]

Core Insights - North China Pharmaceutical (600812.SH) has received the drug registration certificate for Adenosylcobalamin capsules (0.5mg) from the National Medical Products Administration, indicating the product's compliance with basic procurement bidding conditions and its efficacy equivalent to the original product [2] Company Summary - The newly approved product is primarily used for the prevention and treatment of vitamin B12 deficiency, which is increasingly needed when dietary intake is insufficient, as well as for megaloblastic anemia [2] - The approval effectively enhances the company's product pipeline in blood and hematopoietic system medications [2] - However, the sales of formulation products are subject to uncertainties due to potential changes in domestic pharmaceutical industry policies and market conditions [2]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Adenosylcobalamin capsules (0.5mg), indicating a significant advancement in its product pipeline for blood and hematopoietic system medications [1] Group 1: Product Approval - The company has obtained the Drug Registration Certificate for Adenosylcobalamin capsules (0.5mg) [1] - Adenosylcobalamin is primarily used for the prevention and treatment of Vitamin B12 deficiency, particularly in cases of inadequate dietary intake due to various conditions such as consumptive diseases, hyperthyroidism, pregnancy, and lactation [1] - The approval confirms that the product meets the basic entry requirements for centralized procurement bidding and that its efficacy is equivalent to that of the original research product [1]

Market Overview - On June 6, Hong Kong's three major indices experienced a decline, with the Hang Seng Index falling by 0.48% to 23,792.54 points, the Hang Seng Tech Index down by 0.63% to 5,286.52 points, and the Hang Seng China Enterprises Index also decreasing by 0.63% to 8,629.75 points [2][3] - The total market turnover for the day was HKD 235.62 billion, with net inflows from southbound funds amounting to HKD 6.766 billion [2] Pharmaceutical Sector - The pharmaceutical sector saw a significant rally, particularly with CSPC Pharmaceutical Group, which rose by 12.72% on the day, and has accumulated a total increase of 46.4% since May 2 [4][6] - CSPC Pharmaceutical Group announced that its adenosylcobalamin capsules (0.5mg) received drug registration approval from the regulatory authority, which is considered equivalent to passing the consistency evaluation for generic drug quality and efficacy [6] Digital Entertainment Sector - Kuaishou Technology's stock surged by 8.44%, closing at HKD 59.1 per share [6] - According to a report from JPMorgan, Kuaishou's integration of advertising and AI is expected to lead to a revaluation of its stock. The management anticipates that online advertising revenue could see double-digit year-on-year growth by Q2 2025 [8] - The AI capabilities are expected to enhance content recommendation and generation, significantly improving user engagement and retention, while also providing marketing materials and support for advertisers [8] Regulatory Developments - The Hong Kong Financial Secretary, Paul Chan, emphasized the ongoing efforts to promote the internationalization of the Renminbi, including enhancing offshore Renminbi liquidity and expanding the "southbound" trading channels [9] - The "Stablecoin Ordinance" is set to take effect on August 1, 2025, establishing a licensing regime for stablecoin activities in Hong Kong, aimed at promoting a sustainable ecosystem for stablecoins and digital assets [11]